Healthcare / BiotechnologyTSXV
$11.15
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-1.3M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$31M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-65.8%
↓Gross Margin
36.3%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+117.1%
FCF CAGR
—
FCF margin
-5.4%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $23.6M · net income $-6.0M · FCF $-1.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $23.6M | $23.6M | $19.3M | $2.3M | $2.3M |
| Net Income | $-6.0M | $-6.0M | $-1.8M | $-4.6M | $-3.4M |
| EBITDA | $-5.1M | $-5.1M | $62648.00 | $-3.7M | $-1.7M |
| EPS | -2.46 | -2.46 | -0.72 | -2.04 | -1.74 |
| Gross Margin | 36.3% | 36.3% | 38.7% | 38.0% | 24.3% |
| Operating Margin | -3.3% | -3.3% | -3.2% | -184.4% | -126.3% |
| Net Margin | -25.5% | -25.5% | -9.5% | -196.1% | -149.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.16 | 0.26 | 0.26 |
| Current Ratio | 1.56 | 1.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.3M | $-1.3M | $5.6M | $-4.4M | $-3.0M |
| Returns | |||||
| ROE | -65.8% | -65.8% | -13.2% | -32.3% | -21.2% |
| Valuation | |||||
| EV/EBITDA | — | — | 312.84 | — | — |
| P/B | 3.01 | 3.01 | 1.96 | 2.09 | 3.29 |
| Growth & Yield | |||||
| Revenue Growth | 22.2% | 22.2% | 723.1% | 1.7% | — |
| EPS Growth | -241.7% | -241.7% | 64.7% | -17.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.72 → -2.46
Residual
+9.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.